Intercure (INCR) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Intercure (INCR) has outperformed Spero Therapeutics (SPRO) over the past year, losing 50.6% versus a loss of 67.9%. Over five years, INCR leads with a -90.9% price change compared with -95.1% for SPRO. Spero Therapeutics is the larger company by market cap ($43.2 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | SPRO |
|---|---|---|
| Share price | $3.24 | $0.742 |
| Market cap | $42.03M | $43.23M |
| 1-day change | -7.69% | -10.20% |
| YTD return | -28.79% | -68.15% |
| 1-year return | -50.57% | -67.88% |
| 5-year return | -90.87% | -95.09% |
| EPS (TTM) | $-0.95 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | — | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $7.55 | $3.08 |
| 52-week low | $3.12 | $0.73 |
| Distance from 52-week high | -57.09% | -75.91% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +573.85% |
| Average volume | 15.93K | 530.46K |
| Shares outstanding | 12.97M | 58.26M |
| Employees | 285 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed SPRO by 17.3 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
INCR vs SPRO FAQ
Which is bigger, Intercure or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $42.03M for Intercure (INCR).
Which stock has performed better over the past year, INCR or SPRO?
INCR returned -50.57% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.